Komori
KYORIN Pharmaceutical (4569) · InitiativeAdvanced

Organizational and Human Resources Transformation through a Voluntary Retirement Program

First written in FY2024-Q2. 2 of 3 entries say "Advanced", first in FY2024-Q3. Latest entry: FY2025-H1.

3entries
2years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2024-Q2AdvancedFY2024-Q3 – FY2025-H12023: 120232024: 22024
Same theme, other companies
Workforce Restructuring Through a Voluntary Retirement ProgramA theme 67 companies write about · 5 as a headwind · 64 as a tailwind

31 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 67 companies compared. The sentences above are computed from all 67.
Full recordFilings, disclosures and news, newest first
  1. FY2025-H1AdvancedAnnual report

    「Payments of costs related to the voluntary retirement program △265」

    Following the recognition of costs disclosed previously for the voluntary retirement program, ¥265 million in related payments arose during the current interim consolidated accounting period.
  2. FY2024-Q3AdvancedAnnual report

    「As a result of recognizing ¥991 million in gains on sales of investment securities and other items as extraordinary income, and ¥871 million in costs related to the voluntary retirement program and other items as extraordinary losses (see the press release published on 29 September 2023 for details)」

    The voluntary retirement program progressed from the resolution and recruitment policy stage to the recognition of ¥871 million in costs, including special additional payments and outplacement support costs.
  3. FY2024-Q2First statedAnnual report

    「At a meeting of the Board of Directors held on 29 September 2023, the Company resolved to implement the voluntary retirement program described below. The application period was from 1 November through 30 November 2023, and the retirement date was scheduled for 31 January 2024. In addition to the prescribed retirement allowance, special additional payments and outplacement support services were to be provided to applicants.」

    The voluntary retirement program was approved as an organizational and human resources transformation initiative toward realizing Vision 110. The costs were scheduled to be recorded as an extraordinary loss in the fiscal year ending March 2024.
Moved together

"Strengthening the Ultra-Fast Gene Quantification Instrument Business through the Acquisition of Jitas" moved the same way as this thread, in the same document, in 2 of its 3 moves.

22★12
  1. ★This thread
  2. 1Strengthening the Ultra-Fast Gene Quantification Instrument Business through the Acquisition of Jitas2×
  3. 2Decline in Upfront License Fees and Royalty Income2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for KYORIN Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.